

DAFTAR PUSTAKA

- Anderson, G.D., 2004. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. *Neurology* 63, S3–S8. https://doi.org/10.1212/WNL.63.10_suppl_4.S3
- Atmasari, A., Dewi, M.R., Aditiawati, A., Saleh, M.I., 2017. Duration and dose of antiepileptic drugs and serum calcium levels in children. *Paediatr. Indones.* 57, 104. <https://doi.org/10.14238/pi57.2.2017.104-7>
- Bikle, D.D., 2014. Vitamin D Metabolism, Mechanism of Action, and Clinical Applications. *Chem. Biol.* 21, 319–329. <https://doi.org/10.1016/j.chembiol.2013.12.016>
- Brunton, L.L., Knollmann, B.C., Hilal-Dandan, R. (Eds.), 2018. Goodman & Gilman's the pharmacological basis of therapeutics, Thirteenth edition. ed. McGraw Hill Medical, New York.
- Cotterman-Hart, S., 2015. Antiepileptic Drugs, in: *Epilepsy and Brain Tumors*. Elsevier, pp. 171–193.
- Ecevit, C., Aydoğan, A., Kavakli, T., Altinöz, S., 2004. Effect of carbamazepine and valproate on bone mineral density. *Pediatr. Neurol.* 31, 279–282. <https://doi.org/10.1016/j.pediatrneurol.2004.03.021>
- El-Hajj Fuleihan, G., Dib, L., Yamout, B., Sawaya, R., Mikati, M.A., 2008. Predictors of bone density in ambulatory patients on antiepileptic drugs. *Bone* 43, 149–155. <https://doi.org/10.1016/j.bone.2008.03.002>
- Fan, H.-C., Lee, H.-S., Chang, K.-P., Lee, Y.-Y., Lai, H.-C., Hung, P.-L., Lee, H.-F., Chi, C.-S., 2016. The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism. *Int. J. Mol. Sci.* 17. <https://doi.org/10.3390/ijms17081242>
- G., Yamout, B., Mikati, M.A., Demirjian, S., Sawaya, R., El-Hajj Fuleihan, G., 2002. Effect of antiepileptic drugs on bone density in



- ambulatory patients. *Neurology* 58, 1348–1353.
<https://doi.org/10.1212/WNL.58.9.1348>
- Fiest, K.M., Sauro, K.M., Wiebe, S., Patten, S.B., Kwon, C.-S., Dykeman, J., Pringsheim, T., Lorenzetti, D.L., Jetté, N., 2017. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. *Neurology* 88, 296–303.
<https://doi.org/10.1212/WNL.0000000000003509>
- Gani, L.U., How, C.H., 2015. Vitamin D deficiency. *Singapore Med. J.* 56, 433–437. <https://doi.org/10.11622/smedj.2015119>
- Ghodke-Puranik, Y., Thorn, C.F., Lamba, J.K., Leeder, J.S., Song, W., Birnbaum, A.K., Altman, R.B., Klein, T.E., 2013. Valproic acid pathway. *Pharmacogenet. Genomics* 23, 236–241.
<https://doi.org/10.1097/FPC.0b013e32835ea0b2>
- He, X., Jiang, P., Zhu, W., Xue, Y., Li, H., Dang, R., Cai, H., Tang, M., Zhang, L., Wu, Y., 2016. Effect of Antiepileptic Therapy on Serum 25(OH)D₃ and 24,25(OH)₂D₃ Levels in Epileptic Children. *Ann. Nutr. Metab.* 68, 119–127. <https://doi.org/10.1159/000443535>
- Holick, M.F., 2009. Vitamin D status: measurement, interpretation, and clinical application. *Ann. Epidemiol.* 19, 73–78.
<https://doi.org/10.1016/j.annepidem.2007.12.001>
- Hosseinpour, F., Ellfolk, M., Norlin, M., Wikvall, K., 2007. Phenobarbital suppresses vitamin D3 25-hydroxylase expression: A potential new mechanism for drug-induced osteomalacia. *Biochem. Biophys. Res. Commun.* 357, 603–607. <https://doi.org/10.1016/j.bbrc.2007.03.177>
- I. Johannessen, S., Johannessen Landmark, C., 2010. Antiepileptic Drug Interactions - Principles and Clinical Implications. *Curr. Neuropharmacol.* 8, 254–267.
<https://doi.org/10.2174/157015910792246254>



Optimization Software:
www.balesio.com

- ni, R.T.D., Nirmala, S.A., Rahmawati, M., Ghrahani, R., Natalia, .A., Sugianli, A.K., Indrati, A.R., Suwarsa, O., Setiabudiawan, B., 2019. Optimizing ultraviolet B radiation exposure to prevent vitamin

D deficiency among pregnant women in the tropical zone: report from cohort study on vitamin D status and its impact during pregnancy in Indonesia. *BMC Pregnancy Childbirth* 19. <https://doi.org/10.1186/s12884-019-2306-7>

Khanna, S., Pillai, K.K., Vohora, D., 2009. Insights into liaison between antiepileptic drugs and bone. *Drug Discov. Today* 14, 428–435. <https://doi.org/10.1016/j.drudis.2009.01.004>

Kulkarni, B., 2018. Optimal Duration of Sun Exposure for Adequate Cutaneous Synthesis of Vitamin D in Indian Cities: An Estimate Using Satellite-Based Ultraviolet Index Data. *Biomed. J. Sci. Tech. Res.* 6. <https://doi.org/10.26717/BJSTR.2018.06.001313>

Kustiowati, E., Mirawati, D.K., Husna, M., Gunadharma, S., Bintoro, A.C., Suryawati, H., Novitasari, N., Aulina, S., Khairani, A., 2019. Epilepsi, in: Gunadharma, S., Kustiowati, E. (Eds.), *Pedoman Tatalaksana Epilepsi*. Airlangga University Press, Surabaya, pp. 13–14.

Kusumastuti, K., Islamiyah, W.R., Widayanti, J.R., 2019. Bangkitan epileptik, in: Kusumastuti, K., Gunadharma, S., Kustiowati, E. (Eds.), *Pedoman Tatalaksana Epilepsi*. Airlangga University Press, Surabaya, p. 1.

Lanang Sidiartha, I.G., Ngurah Suarba, I.G., Kanya Wati, D., Widyadharma, E., Tjokorda, M., 2018. Correlation Between Calcium Serum Levels and Bone Mineral Density with Duration of Antiepileptic Drugs Uses in Children with Epilepsy. *Biomed. Pharmacol. J.* 11, 857–861. <https://doi.org/10.13005/bpj/1442>

LaRoche, S.M., 2007. A New Look at the Second-Generation Antiepileptic Drugs. *The Neurologist* 13, 133–139. <https://doi.org/10.1097/01.nrl.0000256353.14257.7c>

Łuszczki, J.J., 2009. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. *Pharmacol. Rep.* 61, 197–216. [https://doi.org/10.1016/S1734-1140\(09\)70024-6](https://doi.org/10.1016/S1734-1140(09)70024-6)



- Malabanan, A.O., Turner, A.K., Holick, M.F., 1998. Severe Generalized Bone Pain and Osteoporosis in a Premenopausal Black Female: Effect of Vitamin D Replacement. *J. Clin. Densitom.* 1, 201–204. <https://doi.org/10.1385/JCD:1:2:201>
- Meier, C., Krenslin, M.E., 2011. Antiepileptice and bone health. *Ther. Adv. Musculoskeletal Dis.* 3, 235–243.
- Mintzer, S., Boppana, P., Toguri, J., DeSantis, A., 2006. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. *Epilepsia* 47, 510–515. <https://doi.org/10.1111/j.1528-1167.2006.00460.x>
- Octaviana, F., Khosama, H., 2014. Epidemiologi epilepsi, in: *Pedoman Tatalaksana Epilepsi*. Airlangga University Press, pp. 1–3.
- Pack, A.M., Morrell, M.J., Marcus, R., Holloway, L., Flaster, E., Doñe, S., Randall, A., Seale, C., Shane, E., 2005. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. *Ann. Neurol.* 57, 252–257. <https://doi.org/10.1002/ana.20378>
- Pack, A.M., Morrell, M.J., Randall, A., McMahon, D.J., Shane, E., 2008. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. *Neurology* 70, 1586–1593. <https://doi.org/10.1212/01.wnl.0000310981.44676.de>
- Peacock, M., 2010. Calcium Metabolism in Health and Disease. *Clin. J. Am. Soc. Nephrol.* 5, S23–S30. <https://doi.org/10.2215/CJN.05910809>
- Praticó, A., Pavone, P., Scuderi, M., Volti, G., Bernardini, R., Cantarella, G., Pavone, L., 2009. Symptomatic hypocalcemia in an epileptic child treated with valproic acid plus lamotrigine: a case report. *Cases J.* <https://doi.org/10.4076/1757-1626-2-7394>
- Rafiq, M., Bano, S., Tariq, P.A., 2015. Effect of Antiepileptic Drug Therapy on 25oh Vitamin D Levels. *Pak J Physiol* 11, 24–26.

A.L., Shoback, D.M., 2000. Hypocalcemia: Diagnosis and treatment, in: Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., Lippman, K., Grossman, A., Hershman, J.M., Kaltsas, G., Koch, C.,



Kopp, P., Korbonits, M., McLachlan, R., Morley, J.E., New, M., Perreault, L., Purnell, J., Rebar, R., Singer, F., Trence, D.L., Vinik, A., Wilson, D.P. (Eds.), Endotext. MDText.com, Inc., South Dartmouth (MA).

Sherwood, L., 2016. Control of Ca²⁺ metabolism includes regulation of both Ca²⁺ homeostasis and Ca²⁺ balance., 9th edition. ed. Cengage Learning, Boston, MA, USA.

Sherwood, L., 2013. Control of Ca²⁺ metabolism includes regulation of both Ca²⁺ homeostasis and Ca²⁺ balance., in: Introduction to Human Physiology. Brooks/Cole: Cengage Learning [distributor, Pacific Grove, Calif.; Andover, pp. 757-.

Song, L., 2017. Calcium and Bone Metabolism Indices, in: Advances in Clinical Chemistry. Elsevier, pp. 1–46.

Tamasse, J., 2005. Analisis densitas massa tulang penderita epilepsi yang mendapat pengobatan fenitoin atau fenobarbital jangka panjang dengan morfometri metakarpal.

Valmadrid, C., Voorhees, C., Litt, B., Schneyer, C.R., 2001. Practice Patterns of Neurologists Regarding Bone and Mineral Effects of Antiepileptic Drug Therapy. Arch. Neurol. 58, 1369. <https://doi.org/10.1001/archneur.58.9.1369>

Valsamis, H.A., Arora, S.K., Labban, B., McFarlane, S.I., 2006. Antiepileptic drug and bone metabolism. Nutr. Metab. 3, 36. <https://doi.org/10.1186/1743-7075-3-36>

Verrotti, A., Coppola, G., Parisi, P., Mohn, A., Chiarelli, F., 2010. Bone and Calcium Metabolism and Antiepileptic Drugs. Clin. Neurol. Neurosurg. 112, 1–10. <https://doi.org/10.1016/j.clineuro.2009.10.011>

Yesiltepe Mutlu, G., Hatun, Ş., 2018. Use of Vitamin D in Children and adults: Frequently Asked Questions. J. Clin. Res. Pediatr. Endocrinol. 10, 301–306. <https://doi.org/10.4274/jcrpe.0012>



Lampiran 1

Tabel 1. Karakteristik kadar kalsium serum subyek penelitian yang mengkonsumsi karbamazepin, fenitoin, fenobarbital, dan asam valproat

Kelompok obat	Kalsium			Jumlah	
	Normal	Abnormal			
Jenis Obat	Karbamazepin	n	9	1	10
		%	29.0%	11.1%	25.0%
	Fenitoin	n	9	1	10
		%	29.0%	11.1%	25.0%
	Fenobarbital	n	6	4	10
		%	19.4%	44.4%	25.0%
	Asam Valproat	n	7	3	10
		%	22.6%	33.3%	25.0%
Jumlah	n	31	9	40	
	%	100.0%	100.0%	100.0%	

Tabel 2. Karakteristik kadar vitamin D serum subyek penelitian yang mengkonsumsi karbamazepin, fenitoin, fenobarbital, dan asam valproat

Kelompok Obat	Vitamin D			Jumlah		
	Normal 30-100 ng/dl	Insufisiensi 20-30 ng/ml	Defisiensi <20ng/ml			
Jenis Obat	Karbamazepin	n	0	5	5	10
		%	0.0%	23.8%	27.8%	25.0%
	Fenitoin	n	0	6	4	10
		%	0.0%	28.6%	22.2%	25.0%
	Fenobarbital	n	0	3	7	10
		%	0.0%	14.3%	38.9%	25.0%
	Asam Valproat	n	1	7	2	10
		%	100.0%	33.3%	11.1%	25.0%
Kelompok Obat	Inducer	n	0	14	16	30
		%	0.0%	66.7%	88.9%	75.0%
	Inhibitor	n	1	7	2	10
		%	100.0%	33.3%	11.1%	25.0%
Jumlah	n	1	21	18	40	
	%	100.0%	100.0%	100.0%	100.0%	



Tabel 3. Karakteristik kadar kalsium dan vitamin D serum subyek penelitian yang mengkonsumsi karbamazepin, fenobarbital, fenitoin dan asam valproat < 3 tahun dan ≥ 3 tahun

Kelompok Obat	Kalsium		Nilai P	Vitamin D			Nilai P
	Normal	Abnormal		Normal	Insufisiensi	Defisiensi	
Karbamazepin	< 3 tahun	n 1 % 100,00%	0 0,00%	1,000	1 100,00%	0 0,00%	1,000
	≥ 3 tahun	n 8 % 88,90%	1 11,10%		4 44,40%	5 55,60%	
Fenitoin	< 3 tahun	n 2 % 100,00%	0 0,00%	1,000	1 50,00%	1 50,00%	1,000
	≥ 3 tahun	n 7 % 87,50%	1 12,50%		5 62,50%	3 37,50%	
Fenobarbital	< 3 tahun	n 2 % 100,00%	0 0,00%	0,467	1 50,00%	1 50,00%	1,000
	≥ 3 tahun	n 4 % 50,00%	4 50,00%		2 25,00%	6 75,00%	
Asam Valproat	< 3 tahun	n 2 % 66,70%	1 33,30%	1,000	1 33,30%	2 66,70%	0,202
	≥ 3 tahun	n 5 % 71,40%	2 28,60%		0 0,00%	5 71,40%	

Sumber Data Primer; Uji Chi Square




Tabel 4. Karakteristik kadar kalsium dan vitamin D serum subyek penelitian berdasarkan dosis konsumsi karbamazepin, fenobarbital, fenitoin dan asam valproat

Kelompok Obat		Kalsium			Jumlah	Nilai P	Vitamin D			Jumlah	Nilai P
		Normal	Abnormal				Normal	Insufisiensi	Defisiensi		
Karbamazepin	200 - 400 mg	n 5	1	6	1,000	0	3	4	7	1,000	
	%	83,30%	16,70%	100,00%		0,00%	42.8%	57.2%	100,00%		
	> 400 mg	n 4	0	4	-	0	2	1	3	1,000	
	%	100,00%	0,00%	100,00%		0,00%	66.67%	33.33%	100,00%		
Fenitoin	< 200 mg	n 0	0	0	-	0	1	2	3	1,000	
	%	0,00%	0,00%	0,00%		0,00%	33.33%	66.67%	100,00%		
	200-300 mg	n 9	1	10	1,000	0	3	4	7	1,000	
	%	90%	10%	100,00%		0,00%	42.8%	57.2%	100,00%		
Fenobarbital	100 - 200 mg	n 2	2	4	1,000	0	2	1	3	1,000	
	%	50%	50%	100,00%		0,00%	66.67%	33.33%	100,00%		
	200 - 300 mg	n 4	2	6	1,000	0	4	3	7	1,000	
	%	66.7%	33.3%	100,00%		0,00%	57.2%	42.8%	100,00%		
Azam Valproat	500 mg	n 3	1	4	1,000	0	4	0	4	1,000	
	%	75%	25%	100,00%		0,00%	100,00%	0,00%	100,00%		
	750 - 1000 mg	n 4	2	6	1,000	1	5	0	6	1,000	
%	66.7%	33.3%	100,00%	16,70%		83,30%	0,00%	100,00%			


Sumber Data Primer; Uji Chi Square




Gambar 1. Scatter plot analisis korelasi dosis asam valproat terhadap kadar kalsium serum




Gambar 2. Scatter plot analisis korelasi dosis asam valproat terhadap kadar vitamin D serum




Gambar 3. Scatter plot analisis korelasi durasi konsumsi asam valproat terhadap kadar kalsium serum




Gambar 4. Scatter plot analisis korelasi durasi konsumsi asam valproat terhadap kadar vitamin D serum




Gambar 5. Scatter plot analisis korelasi dosis karbamazepin terhadap kadar kalsium serum




Gambar 6. Scatter plot analisis korelasi dosis karbamazepin terhadap kadar vitamin D serum




Gambar 7. Scatter plot analisis korelasi durasi konsumsi karbamazepin terhadap kadar kalsium serum




Gambar 8. Scatter plot analisis korelasi durasi konsumsi karbamazepin terhadap kadar vitamin D serum




Gambar 9. Scatter plot analisis korelasi dosis fenitoin terhadap kadar kalsium serum




Gambar 10. Scatter plot analisis korelasi dosis fenitoin terhadap kadar vitamin D serum




Gambar 11. Scatter plot analisis korelasi durasi konsumsi fenitoin terhadap kadar kalsium serum




Gambar 12. Scatter plot analisis korelasi durasi fenitoin terhadap kadar vitamin D serum




Gambar 13. Scatter plot analisis korelasi dosis fenobarbital terhadap kadar kalsium serum




Gambar 14. Scatter plot analisis korelasi fanobarbital terhadap kadar vitamin D serum



Gambar 15. Scatter plot analisis korelasi durasi konsumsi fenobarbital terhadap kadar kalsium serum




Gambar 16. Scatter plot analisis korelasi durasi konsumsi fenobarbital terhadap kadar vitamin D serum



Obat	Durasi (> 3 tahun)		Dosis (bergantung tiap obat)	
	Kalsium	Vitamin D	Kalsium	Vitamin D
Asam Valproat	≤ 9	≤ 23.8	≤ 9.5	> 19.8
Karbamazepin			≤ 18.9	≤ 17.9
Feniotin	≤ 9.1	≤ 27.4	≤ 9.3	> 20.7
Fenobarbital	≤ 9.1	≤ 16.2	≤ 7.5	≤ 16.2


Gambar 17. Kurva ROC dosis asam valproat terhadap kadar kalsium serum



Youden index J	0.7500
Associated criterion	≤9.5
Sensitivity	100.00
Specificity	75.00




Gambar 18. Kurva ROC dosis asam valproat terhadap kadar vitamin D serum



Youden index J	0.5000
Associated criterion	>19.8
Sensitivity	100.00
Specificity	50.00




Gambar 19. Kurva ROC durasi konsumsi asam valproat terhadap kadar kalsium serum



Youden index J	0.3810
Associated criterion	≤9
Sensitivity	71.43
Specificity	66.67


Gambar 20. Kurva ROC durasi konsumsi asam valproat terhadap kadar vitamin D serum



Youden index J	0.8571
Associated criterion	≤23.8
Sensitivity	85.71
Specificity	100.00




Gambar 21. Kurva ROC dosis karbamazepin terhadap kadar kalsium serum



Youden index J	0.5833
Associated criterion	≤8.9
Sensitivity	75.00
Specificity	83.33


Gambar 22. Kurva ROC dosis karbamazepin terhadap kadar vitamin D serum



Youden index J	0.5833
Associated criterion	≤17.3
Sensitivity	75.00
Specificity	83.33




Gambar 23. Kurva ROC dosis fenitoin terhadap kadar kalsium serum



Youden index J	0.3333
Associated criterion	≤9.3
Sensitivity	100.00
Specificity	33.33


Gambar 24. Kurva ROC dosis fenitoin terhadap kadar vitamin D serum



Youden index J	0.5714
Associated criterion	>20.7
Sensitivity	57.14
Specificity	100.00




Gambar 25. Kurva ROC durasi konsumsi fenitoin terhadap kadar kalsium serum



Youden index J	1.0000
Associated criterion	≤9.1
Sensitivity	100.00
Specificity	100.00


Gambar 26. Kurva ROC durasi konsumsi fenitoin terhadap kadar vitamin D serum



Youden index J	0.5000
Associated criterion	≤27.4
Sensitivity	100.00
Specificity	50.00




Gambar 27. Kurva ROC dosis fenobarbital terhadap kadar kalsium serum



Youden index J	0.2500
Associated criterion	≤ 7.5
Sensitivity	50.00
Specificity	75.00


Gambar 28. Kurva ROC dosis fenobarbital terhadap kadar vitamin D serum



Youden index J	0.2500
Associated criterion	≤ 16.2
Sensitivity	50.00
Specificity	75.00




Gambar 29. Kurva ROC durasi konsumsi fenobarbital terhadap kadar kalsium serum



Youden index J	0.7500
Associated criterion	≤9.1
Sensitivity	75.00
Specificity	100.00

Gambar 30. Kurva ROC durasi konsumsi fenobarbital terhadap kadar vitamin D serum



Youden index J	0.5000
Associated criterion	≤16.2
Sensitivity	50.00
Specificity	100.00



Lampiran 2



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN KESEHATAN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERJINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431





REKOMENDASI PERSETUJUAN ETIK

Nomor : 249/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 9 April 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20020094	No Sponsor Protokol	
Peneliti Utama	dr. Oktaviana Niken Prawitasari	Sponsor	
Judul Peneliti	Korelasi Antara Durasi dan Dosis Obat Anti Epilepsi Generasi Pertama (Monoterapi) Terhadap Kadar Vitamin D dan Kalsium Serum Pasien Epilepsi Dewasa		
No Versi Protokol	2	Tanggal Versi	18 Maret 2020
No Versi PSP	2	Tanggal Versi	18 Maret 2020
Tempat Penelitian	RS Universitas Hasanuddin, RSUP Dr.Wahidin Sudirohusodo dan RS Jejaring serta Praktek Swasta di Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 9 April 2020 sampai 9 April 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Lampiran 3

INFORMED CONSENT

Peneliti mengharapkan partisipasi Bapak/Ibu/saudara dalam penelitian ilmiah yang dilaksanakan oleh **dr. Oktaviana Niken Prawitasari**

Penelitian ini bertujuan untuk **menganalisis korelasi antara durasi dan dosis obat anti epilepsi generasi pertama (monoterapi) terhadap kadar vitamin D dan kalsium serum pasien epilepsi dewasa.**

Secara keseluruhan, penderita epilepsi di RS Wahidin Sudirohusodo/RSP Universitas Hasanuddin/praktek termasuk Bapak/Ibu/Saudara akan berperan serta dalam penelitian ini. Dengarkan dengan seksama informasi ini sebelum Bapak/Ibu/saudara memutuskan apakah Bapak/Ibu/saudara akan turut berpartisipasi atau tidak. Jangan ragu-ragu untuk bertanya jika ada hal-hal yang belum dimengerti. Bila Bapak/Ibu/saudara memutuskan untuk berpartisipasi kami harap Bapak/Ibu/saudara bersedia dilakukan wawancara, pemeriksaan klinis secara neurologi dan pemeriksaan laboratorium berupa kadar vitamin D dan kalsium serum. Efek samping tindakan berupa rasa nyeri akibat penusukan pembuluh darah vena.

Dalam penelitian ini, peneliti atau petugas yang telah dilatih oleh peneliti akan mewawancarai dan memeriksa Bapak/Ibu/saudara secara klinis neurologi terutama menanyakan tentang riwayat epilepsi yang Bapak/Ibu/saudara alami, dan juga mengenai pengobatan yang Bapak/Ibu/saudara jalani selama ini. Kami akan melakukan pengukuran berat dan tinggi badan kepada Bapak/Ibu/saudara. Selama penelitian Bapak/ibu/saudara tidak dikenakan biaya.

Data-data dikumpulkan dalam penelitian ini akan disimpan dalam data komputer tanpa nama Bapak/Ibu/saudara. Hanya peneliti yang mengetahui data-data Bapak/Ibu/saudara. Hasil penelitian ini mungkin akan dipublikasikan di forum ilmiah terbatas dan jurnal nasional tanpa menampilkan identitas Bapak/ibu/saudara.

Sehubungan dengan penelitian ini, bila timbul pertanyaan mengenai penelitian ini harap menghubungi: **dr. Oktaviana Niken Prawitasari, nomor telepon: 085256220003.**



Lampiran 4

FORMULIR PERSETUJUAN TERTULIS

Saya yang bertanda tangan di bawah ini

Nama :

Umur :

Jenis Kelamin :

Pekerjaan :

Telah membaca dengan seksama keterangan/ informasi yang berkenaan dengan penelitian ini dan setelah mendapat penjelasan, saya mengerti dan bersedia untuk ikut serta dalam penelitian ini.

Nama

Tanda Tangan

Pasien :.....

Saksi :.....

Peneliti :.....



Lampiran 5

**LEMBAR PENGUMPULAN DATA
KORELASI ANTARA DURASI DAN DOSIS OBAT ANTI EPILEPSI
GENERASI PERTAMA (MONOTERAPI) TERHADAP KADAR VITAMIN
D DAN KALSIMUM SERUM PASIEN EPILEPSI DEWASA**

No	Tanggal/tempat Pemeriksaan		
1	Pemeriksaan		
2	Nomor rekam medis		
3	Nama		
4	Umur		
5	Alamat		
6	Jenis Kelamin	Laki-laki	
		Perempuan	
7	Pendidikan saat ini		
8	Pekerjaan		
9	Obat epilepsi yang dikonsumsi	Fenitoin	
		Fenobarbital	
		Karbamazepin	
		Asam valproat	
10	Dosis obat epilepsi yang dikonsumsi		
11	Lama pengobatan hingga pasien diperiksa		
12	Tinggi badan = cm	Obesitas	
	Berat badan = kg	Tidak obesitas	
13	Kadar vitamin D dan Kalsium	Vitamin D	
		Kalsium	



RAW DATA HASIL PENELITIAN VITAMIN D & KALSIMUM

dr.Oktaviana Niken Prawitasari

No	Patient ID	Nama	Tanggal Lahir	Umur	Pendidikan	Alamat	JK	BB	TB	BMI	Jenis Obat	Lama Konsumsi (bulan)	Bebas Kejang (bulan)	Kalsium	Vitamin D 25-OH Total
1	0008200100874	AY	5/26/2000	20	SMA	BTP	M	54	160	21,09	Asam Valproat (Depakote ER) 0-0-1 (500 mg)	18	18	10,8	23,9
2	0167180040062	FAT	9/28/2002	17	SMA	Palangkaraya	F	45	150	20,00	Asam Valproat (Depakote ER) 0-0-1 (500 mg)	60	24	9,8	23,8
3	0008041201233	AT	11/20/1981	38	SARJANA	Toraja	M	62	168	21,97	Asam Valproat (Depakote ER) 2x1 (1000 mg)	48	30	8,9	22,9
4	0173200601403	ATN	5/14/2002	18	SMA	makassar	F	53	160	20,70	Asam Valproat 250-0-250 (500 mg)	120	18	9,7	19,8
5	0167180040073	ASR	4/14/2002	18	SMA	Tarakan	F	42	146	19,70	Asam Valproat 250-0-250 (500 mg)	144	10	8,2	18,9
6	0167170100102	DA	12/31/1979	40	SARJANA	palangkaraya	F	51	155	21,23	Asam Valproat 250-0-500 (750 mg)	240	12	9	20,8
7	0173200601439	MAZ	1/19/1989	31	SARJANA	Makassar	M	70	168	24,80	Asam Valproat 250-0-500 (750 mg)	18	15	9,5	32,7
8	0321200600249	RDL	03/06/86	34	DIPLOMA	palangkaraya	M	60	163	22,58	Asam Valproat 500-0-500 (1000 mg)	38	10	8,8	24,7
9	0008200300155	NA	09/07/89	30	SARJANA	Talasalapang	F	56	154	23,61	Asam Valproat 500-0-500 (1000 mg)	120	20	7,9	23,3
10	0008200700315	AA	10/30/1990	29	SMA	ji sermani	M	63	170	21,80	Asam Valproat 500-0-500 (1000 mg)	20	12	8,1	26,8
11	0008200700423	AF	8/17/2000	20	SMA	JL. Rusa	M	64	166	23,23	Carbamazepine (Bamgetol) 100 mg 2x1 (200 mg)	60	18	7,8	24,2
12	0167200100117	AO	4/21/1994	26	SMA	Minasa Upa	F	46	159	18,20	Carbamazepine (Bamgetol) 200 mg 2x1 (400 mg)	54	26	9,0	20,2
13	0167200100180	UR	09/07/90	29	DIPLOMA	Makassar	F	53	159	20,96	Carbamazepine (Bamgetol) 200 mg 2x1 (400 mg)	60	32	9,1	19,5
14	0173200601060	EF	9/26/1988	31	SD	Makassar	F	50	152	21,64	Carbamazepine (Bamgetol) 200 mg 2x1 (400 mg)	60	24	9,2	20,5
15	173200601348	MJ	07/08/02	18	SMA	BTP	M	48	155	19,98	Carbamazepine (Bamgetol) 200 mg 2x1 (400 mg)	60	18	9,2	17,1
16	0008200200141	RMS	10/07/98	21	SMA	Toraja	F	49	160	19,14	Carbamazepine (Bamgetol) 200 mg 3x1 (600 mg)	54	30	8,9	17,3
17	0008200201252	K	3/19/1988	32	SARJANA	Jl. Tanjung Bunga	F	51	155	21,23	Carbamazepine (Bamgetol) 200 mg 3x1 (600 mg)	96	18	8,8	15,8
18	0008200100669	EE	08/07/95	25	SARJANA	Antang	F	55,7	160	21,76	Carbamazepine (Bamgetol) 200 mg 3x1(600 mg)	96	36	8,8	14,4
19	0008200300166	ETP	07/04/95	25	SMA	Barru	M	58	166	21,05	Carbamazepine (Bamgetol) 500 mg/hari	27	20	9,2	20,8
20	0008200101023	M	09/02/99	20	SMP	Galesong Selatan	F	56	162	21,34	Carbamazepine 200 mg 2x1 (400 mg)	21	12	9,7	23,1
22	0008200100666	J	01/07/00	20	DIPLOMA	-	M	64	164	23,80	Fenitoin 100 mg 2x1 (200 mg)	18	12	9,6	15,9
23	0008200600276	RDL	8/15/1985	35	SMA	selayar	F	50	160	19,53	Fenitoin 100 mg 2x1 (200 mg)	60	24	8,5	20,7
	0600294	S	8/14/1979	41	SMA	sultan alaudin	F	60	165	22,04	Fenitoin 100 mg 3x1 (300 mg)	48	48	9,0	23,5
	0600362	H	12/07/86	33	SARJANA	BTN Minasa Upa	F	50	158	20,03	Fenitoin 100 mg 3x1 (300 mg)	180	36	8,7	13,9
	0700415	MA	5/25/2000	20	SMA	Bulukumba	M	58	160	22,66	Fenitoin 100 mg 3x1 (300 mg)	75	10	9,1	17,8



Optimization Software:
www.balesio.com

28	0008200600222	YF	5/28/2000	20	SMA	tarakan	F	54	150	24,00	Fenitoin 100 mg 3x1 (300 mg)	104	12	8,1	18,7
29	0008200200406	SA	1/17/2000	20	SMP	selayar	F	66	150	29,33	Fenitoin 100 mg 3x1 (300 mg)	60	16	8,4	21,8
30	8200100552	AA	12/18/1998	21	DIPLOMA	daya	M	54	155	22,48	Fenitoin 100 mg 3x1 (300 mg)	48	18	8,8	27,4
31	0416200700044	A	6/16/1990	30	SMA	Tarakan	M	62	160	24,22	Fenitoin 100 mg 3x1 (300 mg)	18	18	9,3	28,7
32	0008200300472	SR	2/13/1984	36	SMA	Jeneponto	F	66	159	26,11	Fenitoin 200 mg 2x1 (200 mg)	120	24	8,7	20,3
33	0008200201506	A	05/01/87	33	SARJANA		M	70	170	24,22	Fenobarbital (Luminal) 50 mg 0-0-4 (200 mg)	144	48	9	17,4
34	0167200100087	DHG	02/05/82	38	SARJANA	Tamalanrea	M	78	172	26,37	Fenobarbital (Sibital) 50 mg 0-0-6 (300 mg)	120	36	9,4	9,7
35	0008200101013	A	10/10/79	40	SD	Majene	M	55	159	21,76	Fenobarbital 30 mg 0-0-5 (150 mg)	35	6	9,3	26,3
36	0008200602617	SM	09/02/83	36	SMP	sungai sedang	M	72	168	25,51	Fenobarbital 30 mg 0-0-5 (150 mg)	120	36	6,7	15,5
37	0008200101558	N	08/08/87	33	SMA	Jeneponto	F	56	158	22,43	Fenobarbital 30 mg 0-0-6 (180 mg)	35	24	10,4	16,7
38	0008200602715	SW	10/30/1997	22	SMP	Baji Gau	F	51	152	22,07	Fenobarbital 30 mg 0-0-7 (210 mg)	84	36	6,7	15,5
39	0008200100652	FAT	6/26/1991	29	SARJANA	-	M	56	164	20,82	Fenobarbital 30 mg 0-0-7 (210 mg)	120	36	9,8	20,1
40	0008200300155	M	8/21/1985	35	SD	S.saddang	M	52	164	19,33	Fenobarbital 30 mg 0-0-7 (210 mg)	84	24	9,1	26,9
41	8200602390	R	9/15/1985	34	SMP	Alaudin	M	72	170	24,91	Fenobarbital 30 mg 0-0-7 (210 mg)	240	6	7,5	16,2
42	0008200100667	H	10/07/80	39	SMP	Dg. Tata	F	58	158	23,23	Fenobarbital 30 mg 0-0-8 (240 mg)	96	8	7,5	19,3

